Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Middletown health presenter outlines rise, risks and control steps for Candida auris
Summary
Doctor Genowind gave an educational briefing to the Middletown Board of Health on April 8, describing Candida auris as an emerging, often drug‑resistant fungal infection that mainly affects hospitalized and long‑term care patients and outlining screening and infection‑control measures.
Doctor Genowind, presenting to the Middletown Board of Health on April 8, 2025, described Candida auris as an emerging fungal pathogen that is increasingly being identified in U.S. patients and poses particular risks for severely ill, hospitalized and long‑term care patients.
Genowind said the organism is notable for drug resistance and diagnostic challenges and summarized public‑health guidance for screening and infection control. "So Candida auris... is essentially a new species of fungus," Genowind said, and "the biggest issue with Candida is it is drug resistant," describing resistance to common azole drugs and growing resistance to amphotericin B and, in a smaller fraction of cases, echinocandins.
The presentation placed the pathogen's U.S. emergence in context: Genowind said…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
